

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Dennis M. Godek, et al. :

APPLICATION NO.: To Be Assigned : Examiner: Elli Peselev
(anticipated)

FILING DATE: Herewith : Group Art Unit: 1623
(anticipated)

TITLE: Azithromycin Combination for Emesis Control in :
Mammals

Mail Stop Patent Application

Hon. Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.


The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Date: Sept. 18, 2003
Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-4288

Respectfully submitted,


Martha G. Munchhof
Attorney for Applicant(s)
Reg. No. 47,811

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>				ATTY. DOCKET NO. PC9940D				SERIAL NO. To Be Assigned					
				APPLICANT Dennis M. Godek, et al.									
				FILING DATE Herewith				GROUP 1623 (anticipated)					
U.S. PATENT DOCUMENTS													
EXAMINER INITIAL	DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
US	5	9	0	0	2	5	7	5/5/99	Breton, et al.	424	639		
FOREIGN PATENT DOCUMENTS													
DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
												YES	NO
EP	0	3	0	7	1	2	8	8/31/88	EPO	A61K	31/71		
EP	0	6	2	7	2	2	1	5/16/94	EPO	A61K	31/435		
EP	0	7	7	3	0	2	6	11/6/96	EPO	A61K	31/445		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)													
			Longmore, et al., "Neuokinin-receptor antagonists: pharmacological tools and therapeutic drugs", <u>Can. J. Physiol. Pharmacol.</u> 75 , pp. 612-621 (1997)										
			Quartara, et al., "The tachykinin NK ₁ receptor. Part II: distribution and pathophysiological roles", <u>Neuropeptides</u> 32 (1), pp. 1-49 (1998)										
			Rosen, et al., "Synthesis and Structure-Activity Relationships of CP-122,721, a second-generation NK-1 Receptor Antagonist", <u>Bioorganic & Medicinal Chemistry Letters</u> 8 , pp. 281-284 (1998)										
			Gardner, et al., "The broad-spectrum anti-emetic activity of the novel non-peptide tachykinin NK ₁ receptor antagonist GR 203040", <u>Br. Journal of Pharmacology</u> 116 , pp. 3158-3163 (1995)										
			Quin Sin Yu, et al., PREV199395089139 BIOSIS 1993 (XP-002196779)										
EXAMINER						DATE CONSIDERED							
<small>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>													

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE

EXPRESS MAIL NO. EV245637124US